Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Tuberculosis and Respiratory Diseases ; : 115-118, 2010.
Artículo en Inglés | WPRIM | ID: wpr-100692

RESUMEN

Paclitaxel has been widely used for treating many solid tumors. Although colonic toxicity is an unusual complication of paclitaxel-based chemotherapy, the reported toxicities include pseudomembranous colitis, neutropenic enterocolitis and on rare occasions ischemic colitis. Genexol-PM(R), which is a recently developed cremophor-free, polymeric micelle-formulated paclitaxel, has shown a more potent antitumor effect because it can increase the usual dose of paclitaxel due to that Genexol-PM(R) does not include the toxic cremophor compound. We report here on a case of a 57-year-old man with advanced non-small cell lung cancer and who developed ischemic colitis after chemotherapy with Genexol-PM(R) and cisplatin. He complained of hematochezia with abdominal pain on the left lower quadrant. Colonoscopy revealed diffuse mucosal hemorrhage and edema from the sigmoid colon to the splenic flexure. After bowel rest, he recovered from his symptoms and the follow-up colonoscopic findings showed that the mucosa was healing. Since then, he was treated with pemetrexed monotherapy instead of a paclitaxel compound and platinum.


Asunto(s)
Humanos , Persona de Mediana Edad , Dolor Abdominal , Carcinoma de Pulmón de Células no Pequeñas , Cisplatino , Colitis Isquémica , Colon , Colon Sigmoide , Colon Transverso , Colonoscopía , Edema , Enterocolitis Neutropénica , Enterocolitis Seudomembranosa , Estudios de Seguimiento , Hemorragia Gastrointestinal , Glutamatos , Guanina , Hemorragia , Membrana Mucosa , Paclitaxel , Platino (Metal) , Polietilenglicoles , Polímeros , Pemetrexed
2.
Tuberculosis and Respiratory Diseases ; : 191-198, 2009.
Artículo en Coreano | WPRIM | ID: wpr-58895

RESUMEN

BACKGROUND: Pemetrexed, a multi-targeted antifolate has been used as a second line treatment against non-small cell lung cancer (NSCLC). We aimed to clarify the efficacy and survival according to line of treatment, histologic type, and expression of thymidylate synthase (TS). METHODS: Ninety-eight patients were treated with pemetrexed as a second line treatment (n=43) or as an additional course of treatment (n=55). TS expression was studied with immunohistochemistry and graded as 0 to 3 based on the extent of expression. RESULTS: The response rate (RR) in 98 subjects was 10.2% and the disease control rate (DCR=PR+SD) was 30.6%. RR and DCR were 12.7% and 32.7% in non-squamous cell carcinoma (NSQC) compared to 7.0% and 27.9% in squamous cell carcinoma (SQC) (p>.05). No significant differences in RR and DCR were observed between a second line group (4.7%, 20.9%) and a further line group (14.5%, 38.2%). A similar trend was observed in the 88 response evaluable subjects. TS was expressed in 28.6% (grade 1), 24.5% (grade 2) and 7.1% (grade 3), respectively, and it was not expressed in 39.8% of subjects. TS expression rate was significantly higher in the SQC (72.1%) compared to NSQC (50.9%, p=0.033). However, the efficacy of pemetrexed was not significantly different by the extent of TS expression. CONCLUSION: Pemetrexed showed efficacy, not only in a second-line setting, but also in further lines of treatment for NSCLC. The efficacy of pemetrexed tended to be higher in patients with NSQC compared to SQC. TS expression rate was significantly higher in SQC compared to NSQC.


Asunto(s)
Humanos , Carcinoma de Pulmón de Células no Pequeñas , Carcinoma de Células Escamosas , Glutamatos , Guanina , Inmunohistoquímica , Timidilato Sintasa , Pemetrexed
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA